Amneal Pharmaceuticals Q2: Fire Numbers, Biosimilars Boom

Amneal Pharmaceuticals Q2 results are blazing hot, with revenues surging 3% to $720M, adjusted EBITDA soaring 13% to $184M, and adjusted EPS skyrocketing 56%. The Specialty segment shines, growing 23% to $128M, driven by CREXONT, RYTARY, and UNITHROID. Brekiya, their first autoinjector for severe migraines, launches in October, targeting peak sales of $50-100M. Affordable Medicines and AvKARE also perform well, with Amneal leveraging U.S. manufacturing and partnerships. Biosimilars are a key focus, with three launched, five in development, and six planned by 2027. XOLAIR biosimilar Phase 3 data looks promising for a $3B market. Debt refinancing cuts costs and reduces leverage. Amneal is poised to become a diversified leader in generics, specialties, and beyond. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/9fd481655b34fb8f